About PASA

Pharmacotherapies for Alcohol and Substance Use Disorders Alliance (PASA) is a coordinated, multicenter collaboration focused on identifying promising compounds and funding further development related to the treatment of alcohol and substance use disorders (ASUD).

learn more here

Information for Researchers

PASA serves as the comprehensive research network for the Department of Defense (DoD) that focuses on developing treatments for ASUD. PASA is designed to conduct research that provides clinically relevant answers and interventions for current Service members and Veterans and to develop treatments for ASUD.

learn more here

PASA Funding Opportunities are now OPEN

learn more here

PASA News

New PASA publication

FKBP5 inhibitors modulate alcohol drinking and trauma-related behaviors in a model of comorbid post-traumatic stress and alcohol use disorder.
Vaccine Targeting Effects Of Fentanyl Developed By Researchers—It Could Help Tackle Opioid Misuse

Researchers at the University of Houston have developed a vaccine that could block the effects of fentanyl and prevent addiction, according to a new study that could unlock solutions to the opioid epidemic as more than 150 people die every day from overdoses connected to synthetic opioids.
Dr. Bryan Cruz and the Scripps Research Institute team will present a poster on Benztropine. Citation below:

Cruz B, Vozella V, Kirson D, Bradley L, Fain K, Crawford M, Carper B, Nolen T, Kosten T, Zorrilla EP, & Roberto M. Benztropine, an FKBP5 inhibitor, reduces ethanol drinking and stress-associated phenotypes in rat model of comorbid post-traumatic stress and alcohol use disorder (June 2021). Research Society on Alcoholism, Virtual Meeting.
Evaluation of the effect of doxasozin and zonisamide on voluntary ethanol intake in mice that experienced chronic intermittent ethanol exposure and stress" by Lopez et al. has been published in Alcohol. Link to publication here: https://doi.org/10.1016/j.alcohol.2020.07.005
As a result of the COVID-19 pandemic, the 2020 Military Health System Research Symposium (MHSRS), scheduled for 24-27 Aug 2020, was cancelled. Despite the cancellation, abstracts by Dr. Christopher Verrico and Dr. Colin Haile were both accepted and can be accessed here: https://mhsrs.amedd.army.mil/SitePages/Home.aspx
Manuscript titled "Evaluation of the effect of doxasozin and zonisamide on voluntary ethanol intake in mice that experienced chronic intermittent ethanol exposure and stress " has been accepted for publication in the journal Alcohol. Information regarding access to the manuscript will be available via the PASA website once published.
May 29, 2020 There will be a virtual investigator meeting for PASA Investigators, Contributors and Collaborators
Dr. Davis will present a poster on Kappa Opioid Receptor Antagonism in the Treatment of Comorbid PTSD and Heavy Alcohol Use at the upcoming VISN 7 Research Summit, November 14, in Birmingham, Alabama.
PASA investigators will be presenting at the 58th Annual Meeting of the American College of Neuropsychopharmacology - https://acnp.org/annual-meeting/
January 7, 2019 PASA PI Dr. Rick Williams and the PASA Consortium are featured in an article on substance abuse in the armed forces – “Teaming Up on Substance Abuse”, Army AL&T magazine, January 2019.
Jun. 27, 2018 New Clinical Funding Opportunity: Pharmacotherapies for Alcohol and Substance Abuse (PASA) Consortium Congressionally Directed Medical Research Program Alcohol and Substance Abuse Disorders Research Program RFA 3 (FY18 Round 1) is open.
Feb. 22, 2018 Funding Opportunity: The Joint Warfighter Medical Research Program (JWMRP) provides an opportunity to advance previously funded DoD or Service medical R&D projects.
Dec. 2, 2016 New Clinical Funding Opportunity: Pharmacotherapies for Alcohol and Substance Abuse (PASA) Consortium Congressionally Directed Medical Research Program Alcohol and Substance Abuse Disorders Research Program RFA 2 (FY17 Round 1) is open.
Sept. 29, 2016 Drug to treat alcohol use disorder shows promise among drinkers with high stress
Sept. 19, 2016 CMDRP Press Release: Pharmacotherapies for Alcohol and Substance Abuse (PASA) Consortium Congressionally Directed Medical Research Program Alcohol and Substance Abuse Disorders Research Program Upcoming Clinical Trial Research Funding Opportunity
Aug. 31, 2016 Submission for the FY16 Round 1 RFA is now closed. The next round of solicitations release date will be announced in Fall 2016 and released in December 2016. Please check the PASA Grant Program page for funding announcements and updates.
Oct. 19, 2015 RTI Press Release: RTI, along with partners Baylor College of Medicine and the Uniformed Services University of Health Sciences, will seek to develop innovative drugs that improve on current treatments.
Sept. 30, 2015 Research Triangle Institute (RTI) was awarded a $10.8M 5-year award from FY14 Alcohol and Substance Abuse Disorders Research Program (ASADRP) Consortia Award Program Announcement.

Participating Organizations

PASA brings together an exemplary team of experts and collaborators who leverage our pharmaceutical company partners to help focus research on compounds ripe for further development.

learn more here

PASA Sponsor

PASA Leadership Centers Contact Us

The Pharmacotherapies for Alcohol and Substance Use Disorders Alliance is funded by the Department of Defense, award # W81XWH-15-2-0077.